Richard Rosenzweig - AngioDynamics Gen VP
| ANGO Stock | USD 9.86 0.22 2.18% |
Insider
Richard Rosenzweig is Gen VP of AngioDynamics
| Age | 57 |
| Address | 14 Plaza Drive, Latham, NY, United States, 12110 |
| Phone | 518 795 1400 |
| Web | https://www.angiodynamics.com |
Richard Rosenzweig Latest Insider Activity
Tracking and analyzing the buying and selling activities of Richard Rosenzweig against AngioDynamics stock is an integral part of due diligence when investing in AngioDynamics. Richard Rosenzweig insider activity provides valuable insight into whether AngioDynamics is net buyers or sellers over its current business cycle. Note, AngioDynamics insiders must abide by specific rules, including filing SEC forms every time they buy or sell AngioDynamics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Richard Rosenzweig over six months ago Disposition of 1356 shares by Richard Rosenzweig of Dentsply Sirona at 33.27 subject to Rule 16b-3 |
AngioDynamics Management Efficiency
The company has return on total asset (ROA) of (0.0584) % which means that it has lost $0.0584 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7644) %, meaning that it created substantial loss on money invested by shareholders. AngioDynamics' management efficiency ratios could be used to measure how well AngioDynamics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of February 2025, Return On Tangible Assets is likely to grow to -0.84. In addition to that, Return On Capital Employed is likely to grow to -0.93. At this time, AngioDynamics' Intangibles To Total Assets are very stable compared to the past year.Similar Executives
| Showing other executives | INSIDER Age | ||
| CCEP CCEP | AtriCure | 52 | |
| Joseph Driscoll | Akoya Biosciences | 59 | |
| Mark Nance | Envista Holdings Corp | 56 | |
| Marilee MBA | Akoya Biosciences | 65 | |
| Christine Tsingos | Envista Holdings Corp | 62 | |
| B Owens | AptarGroup | 66 | |
| Nikolay Samusik | Akoya Biosciences | N/A | |
| Farris Maunsell | Haemonetics | 49 | |
| CPA Parra | Merit Medical Systems | 47 | |
| Vivek Jain | Envista Holdings Corp | 60 | |
| Lloyd Johnson | Haemonetics | 66 | |
| Tonya SPHR | AtriCure | 50 | |
| Jenwei Wu | AptarGroup | 64 | |
| Mark Drury | The Cooper Companies, | 45 | |
| Isabel MareySemper | AptarGroup | 53 | |
| Gerard III | The Cooper Companies, | 60 | |
| Juan Arbona | Envista Holdings Corp | N/A | |
| Joseph Pierce | Merit Medical Systems | N/A | |
| Scott Huennekens | Envista Holdings Corp | 55 | |
| Jason Treft | Merit Medical Systems | N/A | |
| Josh Bennett | Repro Med Systems | N/A | |
Management Performance
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.0584 |
AngioDynamics Leadership Team
Elected by the shareholders, the AngioDynamics' board of directors comprises two types of representatives: AngioDynamics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AngioDynamics. The board's role is to monitor AngioDynamics' management team and ensure that shareholders' interests are well served. AngioDynamics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AngioDynamics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Chad Campbell, Senior Vice President and General Manager, Vascular Access | ||
| Laura Piccinini, Senior International | ||
| David Helsel, Senior Vice President - Global Operations | ||
| Warren Nighan, Senior Vice President-Senior Vice President Quality & Regulatory Affairs | ||
| Scott Centea, Senior Therapies | ||
| James Clemmer, President CEO, Director | ||
| Richard Rosenzweig, Gen VP | ||
| Marna BronfenMoore, Senior Resources | ||
| Kim Seabury, Senior Vice President Information Technology | ||
| Juan Serna, Senior Affairs | ||
| Stephen Trowbridge, Sr. VP, General Counsel and Assistant Secretary | ||
| Saleem Cheeks, Vice Communications | ||
| Benjamin Davis, Senior Vice President Business Development |
AngioDynamics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AngioDynamics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.0584 | ||||
| Profit Margin | (0.78) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 350.07 M | ||||
| Shares Outstanding | 40.47 M | ||||
| Shares Owned By Insiders | 5.62 % | ||||
| Shares Owned By Institutions | 84.12 % | ||||
| Number Of Shares Shorted | 1.47 M | ||||
| Price To Earning | 7.90 X |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AngioDynamics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AngioDynamics. If investors know AngioDynamics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AngioDynamics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.45) | Revenue Per Share | Quarterly Revenue Growth (0.08) | Return On Assets | Return On Equity |
The market value of AngioDynamics is measured differently than its book value, which is the value of AngioDynamics that is recorded on the company's balance sheet. Investors also form their own opinion of AngioDynamics' value that differs from its market value or its book value, called intrinsic value, which is AngioDynamics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AngioDynamics' market value can be influenced by many factors that don't directly affect AngioDynamics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AngioDynamics' value and its price as these two are different measures arrived at by different means. Investors typically determine if AngioDynamics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AngioDynamics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.